About us
Our team understands the effects of neurological diseases on our patients and families, and is committed to providing life-changing therapies with passion, focus, and a sense
of urgency.
Why we do it
Glioblastoma (GBM)
Glioblastoma is the most common, complex, treatment-resistant, and deadliest form of brain cancer. Each year, over 12,000 individuals in the United States are expected to succumb to this disease. The five-year survival rate for glioblastoma patients is a mere 5%, with an average life expectancy of only 12 to 18 months post-diagnosis. Current treatment options include maximal tumor resection followed by radiation therapy with temozolomide. Unfortunately, all tumors recur after initial therapy, and there are no approved treatments for recurrent glioblastoma. The median survival after recurrence is just 6 months. Despite advancements in understanding the genetics and identification of novel drug targets for glioblastoma, the blood-brain barrier remains a significant obstacle, limiting the efficacy of potential new treatments. PNM is developing a more personalized approach, focusing on molecular and regional targeting of tumor cells within the brain to improve both life expectancy and quality of life for glioblastoma patients in a meaningful way.
GBM by the numbers
People die each year from a glioblastoma in the world
Individuals in the US succumb to glioblastoma each year
Five-year survival rate for glioblastoma patients
The number of drugs approved by the FDA in the past 20 years for glioblastoma
What we do
CED & Drug Delivery
The PNM will revolutionize the treatment of neurological diseases by combining targeted drugs with an advanced delivery system that effectively addresses a primary cause of ineffective therapy. Our platform utilizes convection-enhanced delivery (CED) to facilitate the high-concentration delivery of nanoparticles directly into the brain, bypassing the blood-brain barrier (BBB). This will open new therapeutic avenues for a range of neurological conditions, including glioblastoma, stroke, epilepsy, and neurodegenerative diseases such as Parkinson’s and Alzheimer’s. Our first focus is the treatment of Glioblastoma Multiforme.
Who we are
The Precision NeuroMed Story
The PNM Platform
Precision NeuroMed is developing the PNM platform, an innovative drug delivery system poised to transform the treatment of central nervous system (CNS) diseases. Despite progress in understanding the biology of neurological disorders, effective therapies remain elusive due to the challenges posed by the blood-brain barrier (BBB). This highly selective membrane protects the brain by regulating the passage of substances from the blood stream into the brain tissue. While the BBB serves to prevent harmful substances from entering the brain, it also hinders the delivery of many drugs, including potentially beneficial ones, due to their size, polarity, or charge. Consequently, less than 0.1% of small molecule drugs and 0.006% of protein-based drugs penetrate the brain tissue, limiting the therapeutic effectiveness of these treatments. Our platform leverages the BBB to enable direct delivery of nanoparticles (small molecules, proteins, liposomes, and adeno-associated viruses [AAV]) at therapeutic concentrations to the brain, paving the way for more effective treatments.
Integrated Solution for Effective Therapy for Patients with GBM
PNM is revolutionizing glioblastoma multiforme (GBM) treatment through an integrated solution for the precise and effective delivery of IL13-PE38—a potent, targeted drug previously evaluated in a Phase III clinical trial. This drug specifically binds to a unique molecule expressed exclusively on tumor cells, sparing healthy brain tissue. By targeting glioblastoma stem cells, IL13-PE38 demonstrates the potential for a profound impact on patient survival.
PNM’s Founder and CEO, Dr. Sandeep Kunwar, served as the principal investigator of the PRECISE Study (Kunwar et al., Neuro-Oncology, 2010), which established the safety and efficacy of IL13-PE38. While variability in patient outcomes was observed, the study achieved notable success, including 30% of patients remaining disease-free at one year after a single treatment at experienced centers. However, the study lacked access to a specialized convection-enhanced delivery (CED) platform, which limited its potential.
The PNM Platform builds on these findings, addressing critical variables identified in the PRECISE Study to optimize outcomes. By combining targeted therapy with an advanced CED system, PNM aims to significantly improve treatment precision, enhance drug distribution, and achieve superior disease control for GBM patients.